Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

David A. Russler-Germain, Edward R. Scheffer Cliff, Nancy L. Bartlett

Blood (2023) 142 (25): 2216–2219.

https://doi.org/10.1182/blood.2023022048

Published: 2023

Journal Articles

Trends in Medicare Spending on Multiple Myeloma Drugs, 2013 to 2021

Edward R Scheffer Cliff, Mark McGuire, Ghulam Rehman Mohyuddin, Aaron Seth Kesselheim, William B Feldman

Blood (2023) 142 (Supplement 1): 5086.

https://doi.org/10.1182/blood-2023-190372

Published: 2023

Journal Articles

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

George Mellgard, Molly Gilligan, Edward R Scheffer Cliff, Divaya Bhutani, Ghulam Rehman Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2023) 142 (Supplement 1): 4768.

https://doi.org/10.1182/blood-2023-174908

Published: 2023

Journal Articles

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Joshua White, Sara Zhukovsky, Edward R Scheffer Cliff, Rajshekhar Chakraborty, Luciano Costa, Oliver Van Oekelen, Doug Sborov, Ghulam Rehman Mohyuddin

Blood (2023) 142 (Supplement 1): 2402.

https://doi.org/10.1182/blood-2023-185175

Published: 2023

Journal Articles

Assessing the Impact of Blood Cancer Talks , a Novel ‘how I Treat’ Style Podcast on Hematologic Malignancies: A Survey-Based Analysis

Rajshekhar Chakraborty, Edward R Scheffer Cliff, Ashwin Kishtagari

Blood (2023) 142 (Supplement 1): 7270.

https://doi.org/10.1182/blood-2023-184594

Published: 2023

Journal Articles

Pola-R-CHP for DLBCL: cost-effective at first glance

Edward R. Scheffer Cliff, Ankur Pandya

Blood (2022) 140 (25): 2654–2655.

https://doi.org/10.1182/blood.2022017342

Published: 2022

NARROW

Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

Trends in Medicare Spending on Multiple Myeloma Drugs, 2013 to 2021

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Assessing the Impact of Blood Cancer Talks , a Novel ‘how I Treat’ Style Podcast on Hematologic Malignancies: A Survey-Based Analysis

Pola-R-CHP for DLBCL: cost-effective at first glance

Email alerts

ASH Publications

American Society of Hematology

Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

Trends in Medicare Spending on Multiple Myeloma Drugs, 2013 to 2021

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Assessing the Impact of Blood Cancer Talks , a Novel ‘how I Treat’ Style Podcast on Hematologic Malignancies: A Survey-Based Analysis

Pola-R-CHP for DLBCL: cost-effective at first glance

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only